CURE’s liver cancer page features the latest cancer news and updates on liver cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in liver cancer.
October 18th 2024
From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.
September 26th 2024
Second-Line Chemotherapy Combo Shows Survival Benefit in Patients With Advanced Liver Cancer
May 26th 2021The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.
Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma
May 7th 2021Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.
FDA Approves Radiation Therapy for Outpatient Setting in Liver Cancer Subtype
March 19th 2021Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.
Aliqopa With Chemotherapy Did Not Improve Short-Term Progression-Free Survival
January 27th 2021In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.
Novel Therapy Shows Promise in Liver Cancer Subset, May Address ‘Urgent Need for New Therapies’
January 21st 2021“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.
What Patients with Cholangiocarcinoma Should Be Prepared for When Joining a Trial
December 17th 2020A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.